| ALBPS Stock | | | EUR 0.30 0.01 3.45% |
Director
Mr. Waly Dioh is Vice President of Clinical Development at Institut Biophytis SAS. He is Doctor in biology, MBA. Former researcher in genetics and biotechnology at Cargill and Pharmacia, he has experience in plant biotechnology including extraction of macromolecules. He joined Biophytis from 2006 has framed the two clinical studies on products of society, and is currently leading the SARCOB program.
| Age | 54 |
| Professional Marks | MBA |
| Phone | 33 1 44 27 23 00 |
| Web | https://www.biophytis.com |
Biophytis Management Efficiency
The company has return on total asset
(ROA) of
(0.5067) % which means that it has lost $0.5067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(6.8078) %, meaning that it generated substantial loss on money invested by shareholders. Biophytis' management efficiency ratios could be used to measure how well Biophytis manages its routine affairs as well as how well it operates its assets and liabilities.
Biophytis SA has accumulated 6.29
M in total debt with debt to equity ratio
(D/E) of 442.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biophytis SA has a current ratio of 1.76, which is within standard range for the sector. Debt can assist Biophytis until it has trouble settling it off, either with new capital or with free cash flow. So, Biophytis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biophytis SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biophytis to invest in growth at high rates of return. When we think about Biophytis' use of debt, we should always consider it together with cash and equity.
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. The company was founded in 2006 and is headquartered in Paris, France. BIOPHYTIS operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 30 people. Biophytis SA (ALBPS) is traded on Euronext Paris in France and employs 26 people.
Management Performance
Biophytis SA Leadership Team
Elected by the shareholders, the Biophytis' board of directors comprises two types of representatives: Biophytis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biophytis. The board's role is to monitor Biophytis' management team and ensure that shareholders' interests are well served. Biophytis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biophytis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Biophytis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biophytis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Biophytis Stock Analysis
When running Biophytis' price analysis, check to
measure Biophytis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biophytis is operating at the current time. Most of Biophytis' value examination focuses on studying past and present price action to
predict the probability of Biophytis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biophytis' price. Additionally, you may evaluate how the addition of Biophytis to your portfolios can decrease your overall portfolio volatility.